FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024305295> ?p ?o ?g. }

• W2024305295 endingPage "486" @default.
• W2024305295 startingPage "486" @default.
• W2024305295 abstract "P813 Aims: To assess the efficiency of long-term prophylaxis with oral valganciclovir versus sequential intravenous/oral ganciclovir in the prevention of cytomegalovirus (CMV) infection and disease in solid organ transplant recipients. Methods: A cost minimization analysis was performed from the perspective of the Spanish National Health System and differential direct medical costs between both treatments were considered. The efficacy data of valganciclovir regimen was obtained from Paya et al.’sA clinical trial. It was conducted a literature review of published clinical trials in order to obtain the efficacy data of high-risk transplant patients (D+R) treated with sequential intravenous/oral ganciclovir. Resource use, including medication, in the prophylactic treatment with intravenous/oral ganciclovir were retrieved from published literature and a retrospective review of 83 clinical charts of kidney, liver and lung transplant patients in 9 Spanish hospitals. The resources used with valganciclovir were retrieved from Paya et al.’sA clinical trial. The unit costs of resources were obtained from published literature and national databases (€ 2003). The results of the study were expressed in terms of average cost per patient treated with intravenous/oral ganciclovir and valganciclovir. Results: At 12 months post-transplantation, the incidence rate of CMV infection and disease of high risk transplant patients of both long-term prophylactic regimens were comparableA,B. The average cost per patient treated with valganciclovir and sequential intravenous/oral ganciclovir was 3295.9 € and 3715.51 €, respectively. The higher overall costs of intravenous/oral ganciclovir therapy, compared to oral valganciclovir are due to higher drug administration costs. Conclusions: Long-term prophylaxis with oral valganciclovir is a cost-saving option compared to sequential intravenous/oral ganciclovir with similar efficacy rates, thus the oral therapy is a more efficient strategy in the prevention of CMV infection and disease in solid organ transplantation. APaya et al. American Journal of Transplantation, In press BKletzmayr J et al. Transplantation Vol. 70, 1174-1180, No 9, October 27, 2000" @default.
• W2024305295 created "2016-06-24" @default.
• W2024305295 creator A5002954710 @default.
• W2024305295 creator A5017549106 @default.
• W2024305295 creator A5029170224 @default.
• W2024305295 creator A5041855909 @default.
• W2024305295 date "2004-07-01" @default.
• W2024305295 modified "2023-09-24" @default.
• W2024305295 title "COST MINIMIZATION ANALYSIS OF ORAL VALGANCICLOVIR VERSUS INTRAVENOUS AND ORAL GANCICLOVIR IN THE PREVENTION OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN SOLID ORGAN TRANSPLANT RECIPIENTS" @default.
• W2024305295 doi "https://doi.org/10.1097/00007890-200407271-01309" @default.
• W2024305295 hasPublicationYear "2004" @default.
• W2024305295 type Work @default.
• W2024305295 sameAs 2024305295 @default.
• W2024305295 citedByCount "1" @default.
• W2024305295 crossrefType "journal-article" @default.
• W2024305295 hasAuthorship W2024305295A5002954710 @default.
• W2024305295 hasAuthorship W2024305295A5017549106 @default.
• W2024305295 hasAuthorship W2024305295A5029170224 @default.
• W2024305295 hasAuthorship W2024305295A5041855909 @default.
• W2024305295 hasBestOaLocation W20243052951 @default.
• W2024305295 hasConcept C126322002 @default.
• W2024305295 hasConcept C141071460 @default.
• W2024305295 hasConcept C177713679 @default.
• W2024305295 hasConcept C203014093 @default.
• W2024305295 hasConcept C2522874641 @default.
• W2024305295 hasConcept C2776317777 @default.
• W2024305295 hasConcept C2776409557 @default.
• W2024305295 hasConcept C2777732132 @default.
• W2024305295 hasConcept C2777965375 @default.
• W2024305295 hasConcept C2779820661 @default.
• W2024305295 hasConcept C2780727368 @default.
• W2024305295 hasConcept C2781413609 @default.
• W2024305295 hasConcept C2911091166 @default.
• W2024305295 hasConcept C535046627 @default.
• W2024305295 hasConcept C71924100 @default.
• W2024305295 hasConceptScore W2024305295C126322002 @default.
• W2024305295 hasConceptScore W2024305295C141071460 @default.
• W2024305295 hasConceptScore W2024305295C177713679 @default.
• W2024305295 hasConceptScore W2024305295C203014093 @default.
• W2024305295 hasConceptScore W2024305295C2522874641 @default.
• W2024305295 hasConceptScore W2024305295C2776317777 @default.
• W2024305295 hasConceptScore W2024305295C2776409557 @default.
• W2024305295 hasConceptScore W2024305295C2777732132 @default.
• W2024305295 hasConceptScore W2024305295C2777965375 @default.
• W2024305295 hasConceptScore W2024305295C2779820661 @default.
• W2024305295 hasConceptScore W2024305295C2780727368 @default.
• W2024305295 hasConceptScore W2024305295C2781413609 @default.
• W2024305295 hasConceptScore W2024305295C2911091166 @default.
• W2024305295 hasConceptScore W2024305295C535046627 @default.
• W2024305295 hasConceptScore W2024305295C71924100 @default.
• W2024305295 hasLocation W20243052951 @default.
• W2024305295 hasLocation W20243052952 @default.
• W2024305295 hasOpenAccess W2024305295 @default.
• W2024305295 hasPrimaryLocation W20243052951 @default.
• W2024305295 hasRelatedWork W1992751927 @default.
• W2024305295 hasRelatedWork W1996182916 @default.
• W2024305295 hasRelatedWork W2004766863 @default.
• W2024305295 hasRelatedWork W2014246381 @default.
• W2024305295 hasRelatedWork W2038034218 @default.
• W2024305295 hasRelatedWork W2087762810 @default.
• W2024305295 hasRelatedWork W2129588868 @default.
• W2024305295 hasRelatedWork W2158583941 @default.
• W2024305295 hasRelatedWork W2317819115 @default.
• W2024305295 hasRelatedWork W2385743273 @default.
• W2024305295 hasVolume "78" @default.
• W2024305295 isParatext "false" @default.
• W2024305295 isRetracted "false" @default.
• W2024305295 magId "2024305295" @default.
• W2024305295 workType "article" @default.